52855-15-9

Basic information

• Product Name: delta9-tetrahydrocannabinol hemisuccinate
• Synonyms: delta9-tetrahydrocannabinol hemisuccinate
• CAS NO: 52855-15-9
• Molecular Formula: C25H34O5
• Molecular Weight: 414.53446
• Mol File: 52855-15-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 524.9°Cat760mmHg
• Flash Point: 170.2°C
• Appearance: /
• Density: 1.1g/cm³
• Vapor Pressure: 7.62E-12mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: delta9-tetrahydrocannabinol hemisuccinate(CAS DataBase Reference)
• NIST Chemistry Reference: delta9-tetrahydrocannabinol hemisuccinate(52855-15-9)
• EPA Substance Registry System: delta9-tetrahydrocannabinol hemisuccinate(52855-15-9)

Safety Data

• Hazardous Substances Data: 52855-15-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C25H34O5/c1-5-6-7-8-17-14-20(29-23(28)12-11-22(26)27)24-18-13-16(2)9-10-19(18)25(3,4)30-21(24)15-17/h13-15,18-19H,5-12H2,1-4H3,(H,26,27)/t18-,19-/m1/s1

Upstream product

• 108-30-5 succinic acid anhydride 
• 1972-08-3 dronabinol 
• 809279-99-0 tetrahydrocannabinol 

Relevant articles and documents

Rectal bioavailability of Δ-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys

Oral administration of Δ-9-tetrahydrocannabinal (Δ9-THC) was shown to result in low and erratic bioavailability, while the drug showed no bioavailability from various suppository formulations. Δ9-THC-Hemisuccinate was formulated as a prodrug for Δ9-THC in suppositories using Witepsol H15 base. The bioavailability of Δ9-THC from this formulation was evaluated in monkeys. The plasma levels of Δ9-THC and its metabolite 11-nor-Δ9-THC-9-COOH were determined using GC/MS analysis. The calculated bioavailability of Δ9-THC from this formulation was found to be 13.5%. Non-compartmental analysis of the plasma concentration data using statistical moments showed the mean residence time (MRT) for Δ9-THC in the body to be 3 h following iv administration of Δ9-THC or its hemisuccinate ester (3.4 and 2.7 h, respectively), as compared with 5.8 h following rectal administration of the Δ9-THC hemisuccinate. The observed rectal bioavailability of Δ9-THC from suppositories containing the hemisuccinate ester as a prodrug is of significant importance in developing an alternative approach to oral administration of the drug.

TETRAHYDROCANNABINOID ANTIGENS AND METHOD OF USE

The present invention is directed to Δ8-THC and Δ9-THC compounds useful for the covalent attachment to immunogenic molecules to form antigens for the preparation of specific binding molecules to Δ9-Tetrahydrocannabinol, Δ9-Tetrahydrocannabinoids, Δ8-Tetrahydrocannabinol, and Δ8-Tetrahydrocannabinoids, and their derivatives and metabolites. The present invention is directed to the compounds, their method of preparation, cell lines producing the specific binding molecules, methods of using the antigens to produce the specific binding molecules, and test devices containing the antigens, haptens, or specific binding molecules of the invention.